Skip to main content

Table 1 Model variables: transition probabilities

From: Cost-effectiveness of TAS-102 plus bevacizumab versus TAS-102 monotherapy in patients with metastatic colorectal cancer

 

Sensitivity analysis

Base value

Minimum

Maximum

Distribution

Combination therapy

    

 Progression

0.38191794

0.28643845

0.47739742

Binomial

 Death

0.18161864

0.13621398

0.2270233

Binomial

 Complication

0.0846049

0.06345368

0.10575613

Binomial

Monotherapy

    

 Progression

0.55459395

0.41594546

0.69324243

Binomial

 Death

0.26230083

0.19672562

0.32787604

Binomial

 Complication

0.1126958

0.08452185

0.14086975

Binomial